Law Offices of Howard G. Smith reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, Inc. (Alkermes or the Company) (NASDAQ: ALKS) securities between February 17, 2017 and November 1, 2018, inclusive (the Class Period). Alkermes investors have until February 25, 2019 to file a lead plaintiff motion.
Investors suffering losses on their Alkermes investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].
The Complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the U.S. Food and Drug Administration (“FDA”) had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.
If you purchased shares of Alkermes during the Class Period you may move the Court no later than February 25, 2019 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.
WANT TO BUILD A FINANCIAL EMPIRE?
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.